Alx oncology announces first patient dosed in phase 2 investigator-sponsored trial of evorpacept in combination with cetuximab and pembrolizumab in patients with advanced colorectal cancer

South san francisco, calif., aug. 11, 2022 (globe newswire) -- alx oncology holdings inc., (“alx oncology”) (nasdaq: alxo), a clinical-stage immuno-oncology company developing therapies that block the cd47 checkpoint pathway, today announced the initiation of a phase 2 investigator-sponsored study of evorpacept, a next generation cd47 blocker, in combination with erbitux® (cetuximab) and keytruda® (pembrolizumab), merck's anti-pd-1 therapy, in patients with refractory microsatellite stable metastatic colorectal cancer (“mcrc”) who have progressed on at least two lines of systemic therapy.
ALXO Ratings Summary
ALXO Quant Ranking